期刊文献+

PD-1和PD-L1在卵巢上皮性癌组织中的表达及其意义 被引量:18

Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer
原文传递
导出
摘要 目的探讨程序性细胞死亡受体1(PD-1)及其配体(PD-L1)在卵巢上皮性癌(卵巢癌)组织中的表达及其意义。方法选取2002年10月—2013年12月大连医科大学附属第一医院经手术治疗且经病理检查证实为卵巢癌的组织标本180份,包括浆液性癌120份,黏液性癌30份,子宫内膜样癌15份,透明细胞癌15份;从中随机选取50份癌旁的正常卵巢组织标本作为对照。采用免疫组化SP法检测卵巢癌和正常卵巢组织中PD-1及PD-L1的表达,并分析PD-1及PD-L1的表达与卵巢癌患者不同临床病理特征及预后之间的关系。结果(1)卵巢癌和正常卵巢组织中PD-1及PD-L1的表达:PD-1表达于癌组织内浸润的淋巴细胞中,PD-L1表达于癌细胞的细胞膜;在癌旁的正常卵巢组织中PD-1及PD-L1均呈阴性表达。卵巢癌、正常卵巢组织中PD-1及PD-L1的阳性表达率分别均为18.3%(33/180)、2.0%(1/50),两者比较,差异有统计学意义(P<0.01)。(2)不同临床病理特征的卵巢癌组织中PD-1及PD-L1的表达:卵巢癌组织中PD-1、PD-L1的阳性表达率,浆液性癌均高于非浆液性癌(包括黏液性癌、子宫内模样癌、透明细胞癌),手术病理分期为Ⅲ、Ⅳ期者高于Ⅰ、Ⅱ期,发病模式为Ⅱ型者高于Ⅰ型,肿瘤累及侧别为双侧卵巢者高于单侧卵巢者,分别比较,差异均有统计学意义(P<0.05)。(3)不同PD-1、PD-L1表达的卵巢癌患者的生存情况:PD-1阳性、阴性表达患者的中位生存时间分别为35、61个月,PD-L1阳性、阴性表达患者的中位生存时间分别为36、61个月,两者分别比较,差异均有统计学意义(P<0.05)。结论PD-1及PD-L1在卵巢癌组织中的表达均高于癌旁的正常卵巢组织,特别是浆液性癌较为明显;晚期卵巢癌患者PD-1及PD-L1的表达较高,表明PD-1及PD-L1阳性表达是卵巢癌患者预后不良的指标。 Objective To examine the expression of programmed cell death 1(PD-1)and its ligand(PD-L1)in epithelial ovarian cancer(EOC)tissues,and investigate the correlation among their expression,clinicopathological features and prognosis.Methods The specimens of 180 patients with EOC treated in the First Affiliated Hospital of Dalian Medical University from October 2002 to December 2013 were confirmed by pathological examination.The pathological tissue specimens of subtypes,included 120 cases of serous carcinoma,30 cases of mucinous carcinoma,20 cases of endometrioid carcinoma,and 20 cases of clear cell carcinoma.The normal paracancerous tissues of 50 cases randomly selected from the 180 patients as control group.Immunohistochemical SP method was used to detect the expressions of both PD-1 and PD-L1 in epithelial ovarian cancer tissues,and the relationships among their expressions,the clinicopathological parameters and prognosis were respectively analyzed.Results(1)PD-1 was expressed in lymphocytes infiltrated in EOC tissues,and PD-L1 was expressed in the cell membranes of cancer tissues.In all EOC cases,33 cases(18.3%,33/180)of both PD-1 and PD-L1 were highly expressed,and only 1(2.0%,1/50)of control group showed high expression.There was statistically significant difference between two groups(P<0.01).(2)Among the four subtypes tissue specimens of EOC,the high expression rate of PD-1 was 25.0%(30/120)for serous carcinoma,3/15 for endometrioid carcinoma,0(0/30)for mucinous carcinoma,and 0(0/15)for clear cell carcinoma.The high expression rate of PD-L1 was 23.3%(28/120)for serous carcinoma,3.3%(1/30)for mucinous carcinoma,2/15 for endometrioid carcinoma,and 2/15 for clear cell carcinoma.Both PD-1 and PD-L1 expressions in the four sub-types of tissue specimens were significantly different(P<0.05).The high expression rate of both PD-1 and PD-L1 was 9.2%(8/87)in the early stage and 26.9%(25/93)in the late stage.There was a statistically significant difference between the two groups(P<0.01).Similarly,the expression of both PD-1 and PD-L1 were significantly higher in the cases of high-grade EOC(typeⅡ)than those of low-grade(typeⅠ)and in the cases of EOC distributed bilaterally than that distributed unilaterally,and there were statistically significant differences(P<0.05).(3)The Kaplan-Meier survival analysis showed that the survival time were respectively 35 and 36 months in the cases with high expressions of both PD-1 and PD-L1,and the survival time were the same as 61 months in the cases with low expression of both PD-1 and PD-L1,and the comparison was statistically significant(P<0.05).Conclusions The expression levels of PD-1 and PD-L1 in EOC tissues are higher than those in adjacent tissues,especially in serous carcinomas.The expression of both PD-1 and PD-L1 is higher in specimens of the patients with advanced stages.The results showed that the high expression of both PD-1 and PD-L1 is an indicator of poor prognosis of patients suffering from EOC.
作者 鞠策 高景春 张朋新 张凯娜 杨森 亢铁金 赵红珍 祁文静 张秋萍 孔繁斗 关宏伟 石红 Ju Ce;Gao Jingchun;Zhang Pengxin;Zhang Kaina;Yang Sen;Kang Tiejin;Zhao Hongzhen;Qi Wenjing;Zhang Qiuping;Kong Fandou;Guan Hongwei;Shi Hong(Department of Obstetrics and Gynecology,First Affiliated Hospital,Dalian Medical University,Dalian 116011,China;Department of Pathology,First Affiliated Hospital,Dalian Medical University,Dalian 116011,China;Department of Obstetrics and Gynecology,Fushun Central Hospital of Liaoning Province,Fushun 113006,China)
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2020年第8期529-534,共6页 Chinese Journal of Obstetrics and Gynecology
关键词 卵巢上皮 卵巢肿瘤 程序性细胞死亡受体1 免疫组织化学 Carcinoma,ovarian epithelial Ovarian neoplasms Programmed cell death 1 receptor Immunohistochemistry
作者简介 通信作者:高景春,Email:jingchun_gao@hotmail.com。
  • 相关文献

参考文献2

二级参考文献33

  • 1Hodi F S,O'Day S J, McDermott D F, et al. Improved survival with ipilimumab in patients with metastasis melanoma [J]. N Engl J Med, 2010,363(8) : 711- 723.
  • 2Robert C,Thomas L,Bondarenko I,et al. Ipilimumab plus dacarba- zinc for previously untreated metastatic melanoma[J]. N Engl J Med,2011,364(26) :2517-2526.
  • 3Eggermont A M,Chiarion-Sileni V,Grob J J ,et al. Ipilimumab ver- sus placebo after complete resection of stage m melanoma: initial efficacy and safety results from the EORTC 18071 phase 111 trial [J]. J Clin Oncol, 2014,32(18 suppl) = LBA9008.
  • 4Lynch T J, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as firstqine treatment in stage Ill B/ IV non-small cell lung cancer, results from a randomized, double- blind,multicenter phase II study[J]. J Clin Oncol, 2012,30 (17) : 2046-2054.
  • 5Kwon E D,Drake C G,Scher H I, et al. Ipilimumab versus placebo after radiotherapy in patient with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043) = a multicentre, randomized, double-blind phase 3 trial [J]. Lancet Oncol,2014,15(7) :700-712.
  • 6Ribas A, Kefford R, Marshall M A, et al. Phase III randomized clini- cal trial comparing tremelimumab with standard-care chemotherapy in patients with advanced melanoma[J]. J Clin Oncol, 2013,31 ( 5 ) = 616-622.
  • 7Calabro L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label,single-arm, phase 2 trial [J]. Lancet Oncol, 2013, 14 (11):1104-1111.
  • 8Robert C,Ribas A, Wolchok J D, et al. Anti-programmed-death-re- ceptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma:a randomized dose-comparison cohort of phase 1 trial[J]. Lancet,2014,384(9948) :1109-1117.
  • 9Ribas A, Hodi F S,Kefford R,et al. Efficacy and safety of the anti- PD-1 monoclonal antibody MK-3475 in 411 patients(pts) with mel- anoma (MEL)[J]. J Clin Oncol,2014,32(18 suppl)=LBA9000.
  • 10Garon E B,Leighl N B,Rizvi N A,et al. Safety and clinical activity of MK-3475 in previously treated patients(pts) with non-small cell lung cancer (NSCLC) [J]. J Clin Oncol, 2014,32 (15 suppl):abstr 8020.

共引文献6

同被引文献138

引证文献18

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部